Abstract:Abstract: Objective To observe the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) and pramipexole in mid and late Parkinson’s disease (PD) with depression. Methods 92 patients with mid and late PD and depression were randomly treated with pramipexole (control group) or rTMS plus pramipexole (observation group) for 12 weeks. Depression, sleep quality, quality of life, and serum inflammatory factors were detected by Hamilton Depression Scale (HAMD), Parkinson’s Disease Sleep Scale (PDSS), Parkinson’s Disease Quality of Life Scale (PDQ-39), and enzymelinked immunosorbent assay, respectively. Results After 12 weeks of treatment, HAMD, PDQ-39 and inflammatory factors (IL-6, IL-1β and IL-8) were lower but PDSS was higher in observation group compared with control group (P<0.01 or 0.05). Conclusion Combined rTMS and pramipexole can improve depression, sleep quality and quality of life in patients with mid and late PD and depression.